Drug · DIN 02415992
EYLEA
2 MG/50 MCL SINGLE-USE VIAL
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since December 23, 2013; first marketed December 23, 2013.
- Drug Identification Number (DIN)
- 02415992
- Company (DIN owner)
- Bayer Inc.Elkhart, Indiana, United States
- Schedule
- Prescription; Schedule d
- Dosage form
- Solution
- Route
- Intravitreal
- Therapeutic class (ATC)
- Aflibercept S01LA05
- Class
- Human
- Record last updated
- August 13, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| AFLIBERCEPT | 2 MG | 0.05 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- November 28, 2014: NOC 16368Supplement to a New Drug Submission (SNDS) · New indication: eylea is indicated for the treatment of diabetic macular edema (dme)
- October 16, 2014: NOC 16179New Drug Submission (NDS)
- November 8, 2013: NOC 14893New Drug Submission (NDS)
Other DINs named EYLEA
- DIN 02505355 · Marketed